12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb Company’s NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced interim results from a Phase IIb clinical trial (COMMAND-1) of 395 treatment-naïve, genotype 1 and 4 hepatitis C infected patients in which two doses of the investigational NS5A replication complex inhibitor daclatasvir (BMS-790052), in combination with peginterferon alfa and ribavirin (alfa/RBV), achieved higher virologic response rates through Week 12 than the alfa/RBV control group, with comparable rates of adverse events. The data were reported at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco.